Zai Lab Bags China NMPA Nod of Augtyro To Treat Patients with NSCLC

Zai Lab Limited, a biotechnology firm, declared that the National Medical Products Administration (NMPA) in China has endorsed the New Drug Application (NDA) for Augtyro (repotrectinib) for the therapy of grown-up patients with privately progressed or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). The endorsement depends on the vital Pike 1 review, an open-mark, single-arm, stage 1/2 preliminary that assessed repotrectinib in TKI-guileless and TKI-pretreated patients with ROS1-positive NSCLC.  

“We are pleased with NMPA’s approval of Augtyro for the treatment of patients with ROS1-positive NSCLC in China. There is a significant unmet need for these patients given the limited durability of benefit due to the emergence of resistance with existing therapies, eventually leading to tumour progression,” said Rafael G. Amado, M.D., president, head of global oncology research and development at Zai Lab. “We appreciate the NMPA for their thorough assessment of Augtyro, recognizing its potential to address the unmet medical need in China.”

“Despite existing earlier generation TKIs for ROS1-positive NSCLC, there remains an unmet need for new treatment options that support important clinical goals, such as durable therapeutic response,” said Dr. Shun Lu, M.D., Ph.D., Chief of Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University. “The TRIDENT-1 study showed that treatment with repotrectinib results in high response rates with promising durability in patients with ROS1-positive NSCLC, across TKI-naïve and TKI-pretreated settings, including in the presence of intracranial disease. Based on this study, repotrectinib has the potential to become a new standard of care for these patients.”

In June 2023, China's NMPA acknowledged the NDA for Augtyro for the treatment of grown-up patients with privately progressed or metastatic ROS1-positive NSCLC, with need survey conceded in May 2023.